More Special Issues

About the Journal

American Journal of Life Sciences

(ISSN Online: 2328-5737)

About the Special Issue

A Special Issue of American Journal of Life Sciences (ISSN Online 2328-5737)

Deadline for manuscript submissions: Jul. 20, 2020

The urological research has been emphasizing in recent years by important scientific discoveries and has become a north for urology. The main field linked to advances in this segment is translational research. Nowadays, we already know that some pharmacological treatments for some pathologies can generate adverse effects and provoking the appearance of new pathologies secondary to the treatment. In addition, works in this direction have generated good publications in newspapers with considerable impact in the academic environment and a considered number of citations on these scientific studies. Morphological studies of pharmacological treatments, experimental surgical techniques and dietary supplementation models have become a great tool for understanding the mechanisms of progression of pathophysiology with benign prostatic hyperplasia and prostate cancer. Today we can already understand the important role of antioxidants as a tool for partial and total nephrectomies. The purpose of this special edition will be to open an abstracts submission in this segment, which will allow a good collection of scientific studies of quality studies. Enabling a greater number of citations in two years. The methodology for choosing the works: we will consider submissions of original scientific articles, meta analyzes, systematic reviews of the literature and letter to the editor of the special edition. In addition, only papers that have been approved by the ethics committee of the institution where the scientific work was done will be accepted.

Aims and Scope:

  1. Urology
  2. Nephrology
  3. Benign prostatic hyperplasia
  4. Prostate cancer
  5. Nutrition and metabolic diseases
  6. Nephrectomies and antioxidants
Lead Guest Editor
  • Marcello Henrique Araujo Da Silva

    Department of Anatomy,Rio de Janeiro State University , Rio de Janeiro, Brazil

Guest Editors
  • Gabriela Faria Buys Gonçalves

    Department of Anatomy,Rio de Janeiro State University , Rio de Janeiro, Brazil

  • Roger Gaspar Marchon

    Department of Anatomy,Rio de Janeiro State University , Rio de Janeiro, Brazil

View All Guest Editors
Latest Article
  • Authors: Nathan Walter Leibacher, Marcello Henrique Araujo Da Silva

    Abstract: In the United States, tamsulosin is the most prescribed drug for benign prostatic hyperplasia (BPH) treatment. However, less is known about the adverse effects and mechanism of action of the drug in the organism. So, the aim of this review is to evaluate the benefits and harms of tamsulosin therapy in patients with BPH. A literature analysis was realized using the database of the National Center for Biotechnology Information (NCBI) MEDLINE®. The data collection was carried out in a retrospective of 10 years from 2008. Thus, we considered some measurements parameters used in different studies for a reliable comparison of the works. Tamsulosin has been characterized as an effective treatment for BPH. However, some studies demonstrate that the epithelial elements remain proliferative even after the administration of the drug and may be involved in the continuous growth of the gland. Also, tamsulosin can directly impact on the ejaculation process, cognitive functions and mental health of men. BPH affects approximately 50% of men between 50 and 60 years old. Beyond that, 90% of men in their eighth decade of life will present anatomical evidence of BPH. Therefore, the treatment with tamsulosin, an α1-adrenergic antagonist that promotes the relaxation of the prostate smooth muscle, is essential to diminish the gland size and restore the urinary flow. However, its administration must be assessed for a better response and lower risk of adverse effects in those patients.

    Publication Date: Sep. 11, 2019 Views: Downloads:
Call for Papers

This special issue is open for submissions of original research. It accepts full papers, abstracts and tentative paper titles. The submission deadline is Jul. 20, 2020. Authors are encouraged to contribute research in related fields to the special issue.

Manuscript Submission

Publishing research works with Science Publishing Group is simple and efficient. Here are 3 ways for you to submit your manuscript.

1. Quick Submission

Quick Submission helps authors submit their manuscripts in a simple and quick way.

Special Issue Title*
Advances in Urology and Nephrology in the 21st Century

Or click here to select another Special Issue that is more appropriate for your manuscript.

Select Another Special Issue
Step 1-Please Select a Category  *
  • Category
Step 2-Please Select a Special Issue  *
Special Issue Title
Article Processing Charge

1. Please select your research category in the left column first.
2. Then select a Special Issue to submit your paper in the right column.

Cancle Confirm
Type of Submission*

The submission can be in the forms of full paper, abstract or the tentative title of a paper.

Upload Full Paper*

1. Allow only .doc, .docx and .tex format.
2. Files should not exceed 20MB.

Paper Title*


Tentative Date for Submitting the Full Paper*

The submission deadline is Jul. 20, 2020.

Paper Title*

Tentative Date for Submitting the Full Paper*

The submission deadline is Jul. 20, 2020.

First Name*

Last Name*

Email Address*

A follow-up email will be sent to the given email address within 3 working days.

2. Email Submission

Manuscripts can also be submitted by the email. Please send your manuscript directly to this email address:

Please type "Advances in Urology and Nephrology in the 21st Century Manuscript Submission" as the subject of your email.

3. Online Submission

Authors can also log into the Online Submission System to finish the submission: